Medicines Discovery Catapult will conduct an in vivo 18F imaging and toxicity study.
The Medicines Discovery Catapult will conduct an in vivo 18F imaging and toxicity study in naive and cancer xenograft bearing mice of our HER2 targeting apoferritin anti-cancer drug delivery platform.
Buyer
UNIVERSITY OF NOTTINGHAM (THE)
Value
£76,536
Published
27 Jan 2023
Closes
4 May 2022
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Direct
Category
Services
Contract starts
4 May 2022
Contract ends
5 May 2022
CPV classifications
73100000
Research and experimental development services
Lots
Lot default Medicines Discovery Catapult will conduct an in vivo 18F imaging and toxicity study.
£76,536
The Medicines Discovery Catapult will conduct an in vivo 18F imaging and toxicity study in naive and cancer xenograft bearing mice of our HER2 targeting apoferritin anti-cancer drug delivery platform.
Delivery: East Midlands · United Kingdom, East Midlands, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
7 Jul 2022
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.